Innovations in the treatment and prevention of influenza in children and adolescents

In September 2024, an Expert Council via videoconference was held to discuss innovative approaches to the tactics of diagnosis and therapy of influenza in children and adolescents in Russian Federation.

Influenza is characterized by high morbidity and mortality, leading to 28,000 deaths annually worldwide among children.

Influenza causes significant economic damage, ranking 4th among all infectious diseases in 2023 in Russian Federation. During the 2022­2023 period, there was an increase in influenza incidence with a traditionally high rate of infection among children. Newborns, children under 5 years old, and children with comorbidities are at high risk for complications. An analysis of influenza mortality shows that comorbidity is an aggravating factor in almost half of the cases.

Timely diagnosis and etiotropic therapy are key in the treatment of influenza. The focus should be on etiological confirmation of the diagnosis within the first 24 hours from disease manifestation to prescribe specific antiviral therapy. Although laboratory confirmation of the diagnosis is recommended, during periods of high incidence, the diagnosis can be made based on clinical and epidemiological data. For final verification of the “influenza” diagnosis, the widespread use of certified rapid tests is proposed.

According to the updated WHO guidelines published in September 2024, two medicines are recommended for the treatment of influenza — baloxavir and oseltamivir. Baloxavir marboxil significantly reduces the virus shedding time and has a favorable safety profile for children and adolescents. This makes it the medicine of choice, especially in cases of high risk of complicated influenza infection.

Given the high importance of influenza in the structure of childhood morbidity, it is crucial to continue improving methods of prevention, diagnosis, and treatment of this disease, especially in children.

1. Paget J, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019 Dec;9(2):020421.

2. Rukovodstvo po infekcionnym boleznjam. V 2 kn. Kn.2./ Pod red. akad. RAMN, prof. Ju.V. Lobzina i prof. K.V. Zhdanova. – 4-e izd., dop i pererab. – Sankt-Peterburg, 2011. Chast’ 2. P. 7-19.. (in Russian)

3. Nayak J, Hoy G, Gordon A. Influenza in Children. Cold Spring Harb Perspect Med. 2021 Jan 4;11(1):a038430.

4. Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, Likos AM, Posey DL, Klimov A, Lindstrom SE, Balish A, Medina MJ, Wallis TR, Guarner J, Paddock CD, Shieh WJ, Zaki SR, Sejvar JJ, Shay DK, Harper SA, Cox NJ, Fukuda K, Uyeki TM; Influenza Special Investigations Team. Influenzaassociated deaths among children in the United States, 20032004. N Engl J Med. 2005 Dec 15;353(24):2559-67.

5. Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, Zhang J, Wang X, Wang G. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021 Jun 28;37:100986.

6. O sostojanii sanitarno-jepidemiologicheskogo blagopoluchija naselenija v Rossijskoj Federacii v 2019 godu: Gosudarstvennyj doklad.– M.: Federal’naja sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka, 2020.– 299 p. (in Russian)

7. O sostojanii sanitarno-jepidemiologicheskogo blagopoluchija naselenija v Rossijskoj Federacii v 2023 godu: Gosudarstvennyj doklad. Moskva: Federal’naja sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka, 2024. – 364 p. (in Russian)

8. Benitez et al. Predictors of seeking care for influenza like illness using a novel digital study design. ESWI 2021. Abstract 257.

9. Klinicheskie rekomendacii “Gripp u vzroslyh”, Minzdrav Rossii, 2022. – 104p. Available at: https://cr.inzdrav.gov.ru/ recomend/749_1. Date of access 16 October 2024. (in Russian)

10. WHO. Guidelines for the clinical management of severe illness from influenza virus infections. March 2022: Available at: https://apps.who.int/iris/handle/10665/352453. Date of access 16 October 2024.

11. SanPiN 3.3686-21 «Sanitarno-jepidemiologicheskie trebovanija po profilaktike infekcionnyh boleznej», XXXIV. Profilaktika grippa i drugih ostryh respiratornyh virusnyh infekcij, p. 2659. (in Russian)

12. Klinicheskie rekomendacii «Gripp. Vozrastnaja gruppa: deti». Proekt. 2024. Available at: https://portalcr.minzdrav.gov.ru/viewCR/2384. Date of access 16 October 2024. (in Russian)

13. Zdravoohranenie v Rossii. 2023: Stat. sb./Rosstat. – M., 2023. – 179p. (in Russian)

14. Pisareva M.M., Eder V.A., Buzitskaya Zh.V., Musaeva T.D., Afanaseva V.S., Go A.A., Obraztsova E.A., Sukhovetskaya V.F., Komissarov A.B. Etiological structure of influenza and other ARVI in St. Petersburg during epidemic seasons 20122016. Voprosy Virusologii (Problems of Virology, Russian journal). 2018; 63(5): 233-239. (in Russian)

15. Prikaz Minzdrava Rossii ot 10 maja 2017 g. №203n «Ob utverzhdenii kriteriev ocenki kachestva medicinskoj pomoshhi». Available at: https://docs.cntd.ru/document/436733768 Date of access 16 October 2024. (in Russian)

16. Prikaz Departamenta zdravoohranenija goroda Moskvy ot 18.09.2024 g. №811 «Ob utverzhdenii pravil organizacii stacionarnoj i specializirovannoj medicinskoj pomoshhi pacientam s grippom, ORVI, novoj koronavirusnoj infekciej (COVID-19), vnebol’nichnymi pnevmonijami na jepidemiologicheskij sezon 2024 – 2025 godov». (in Russian)

17. Muthuri SG, Venkatesan S, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041-4. Epub 2014 Mar 19.

18. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018;379:913-23.

19. WHO. Clinical practice guidelines for influenza. September 2024. . Available at: https://app.magicapp.org/#/guideline/jlPRdj Date of access 16 October 2024.

20. Baker J, Block SL, Matharu B, et al. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700-705.

21. Gorelov A.V., Lobzin Yu.V, Zhdanov K.V., Babachenko I.V., Rychkova S.V., Dmitriev A.S. Baloxavir for influenza in children and adolescents: a systematic review of controlled trials. Infekc. bolezni (Infectious Diseases). 2024; 22(3): 83–91. (In Russian). DOI: 10.20953/1729-9225-2024-3-83-91. (in Russian)